Friday, October 12, 2012

Aerial BioPharma raises $5.67 million

CED Member Aerial BioPharma, a biotech startup led by serial life science entrepreneur Moise Khayrallah, announced last week that the company has now raised $5.67 million of its $12 million.

According to an SEC filing, Aerial raised $5.67 million from 23 investors as of Thursday, October 11, 2012. Investors include Rex Health Ventures and 3G Capital, and "about 10 other individual angel investors from NC," said Moise Khayrallah, CEO.

The additional funding will be used to complete the Phase II –development activities for Aerial’s N05 product for narcolepsy and complete the non-clinical program necessary to file the  IND for the PAP, Aerial’s biologic for the treatment of acute and chronic pain, said Khayrallah in an email to CED.

The U.S. Food and Drug Administration Office of Orphan Products Department recently granted orphan designation for Aerial's N05 program in narcolepsy. According to Khayrallah, Aerial has "initiated a Phase 2b study in 90 patients with narcolepsy to confirm the efficacy and safety data obtained in the completed Phase 2a study in more patients for a longer duration of treatment."

Khayrallah also reports that two other programs at Aerial are progressing at a good pace. Aerial can now manufacture enough protein in a mammalian cell line to launch non-clinical toxicology studies for Aerial's PAP program, said Khayrallah. The first non-clinical study was initiated early this month, said Khayrallah.

Aerial also runs a granisetron nasal spray program, and Khayrallah reports that the company has agreed with the FDA on a development plan and are proceeding with pharmacokinetic and Phase 3 studies.

This $5.67 million is a strong investment, and allows Aerial to continue the company's programs without interruption. Aerial continues its plans to raise the remaining portion of the Series A financing- $3 million in January and the rest in early 2014, said Khayrallah.

Note: Moise Khayrallah, CEO of Aerial BioPharma is a current CED Board of Directors member. 

No comments:

Post a Comment